Trial Profile
A Phase II Study of Ruxolitinib Pre-, During- and Post-Hematopoietic Stem Cell Transplantation for Patients With Primary or Secondary Myelofibrosis
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Jan 2024
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Myelofibrosis
- Focus Therapeutic Use
- 12 Dec 2023 Updated Results presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 25 Oct 2023 Planned End Date changed from 1 Dec 2024 to 1 May 2025.
- 25 Oct 2023 Planned primary completion date changed from 1 Dec 2023 to 1 May 2024.